Cantor Fitzgerald Initiates Coverage On bluebird bio with Neutral Rating
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Eric Schmidt has initiated coverage on bluebird bio (NASDAQ:BLUE) with a Neutral rating.
October 17, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald has initiated coverage on bluebird bio with a Neutral rating, indicating no clear short-term price direction.
The Neutral rating from Cantor Fitzgerald suggests that the analyst does not see a clear price direction for bluebird bio in the short term. This could mean that the stock's price could go either way, depending on various factors such as market conditions and company performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100